New treatment options are needed for patients not eligible for ICIs, and ETB, a target already approved by the Food and Drug Administration, represents a promising option for melanoma treatment, as evidenced by numerous therapeutic trials targeting endothelin (ET) receptors [4–6]. Here, EDNRB is linked to melanoma.